OtherClinical Investigations (Human)
Side effects of CXC-chemokine receptor 4 – directed Endoradiotherapy with Pentixather prior to Hematopoietic Stem Cell Transplantation
Sabine Maurer, Peter Herhaus, Romina Lippenmeyer, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, H. Carlo Maurer, Andreas K. Buck, Hans-Jürgen Wester, Hermann Einsele, Götz-Ulrich Grigoleit, Ulrich Keller and Constantin Lapa
Journal of Nuclear Medicine March 2019, jnumed.118.223420; DOI: https://doi.org/10.2967/jnumed.118.223420
Sabine Maurer
1 III. Medical Department, Hematology and Medical Oncology, Technische Universität München, Germany;
Peter Herhaus
1 III. Medical Department, Hematology and Medical Oncology, Technische Universität München, Germany;
Romina Lippenmeyer
2 Department of Nuclear Medicine, University Hospital Würzburg, Germany;
Heribert Hänscheid
2 Department of Nuclear Medicine, University Hospital Würzburg, Germany;
Malte Kircher
2 Department of Nuclear Medicine, University Hospital Würzburg, Germany;
Andreas Schirbel
2 Department of Nuclear Medicine, University Hospital Würzburg, Germany;
H. Carlo Maurer
3 II. Medical Department, Gastroenterology and Hepatology, Technische Universtät München, Germany;
Andreas K. Buck
2 Department of Nuclear Medicine, University Hospital Würzburg, Germany;
Hans-Jürgen Wester
4 Pharmaceutical Radiochemistry, Technische Universität München, Germany;
Hermann Einsele
5 II. Medical Department, Hematology and Medical Oncology, University Hospital Würzburg, Germany;
Götz-Ulrich Grigoleit
5 II. Medical Department, Hematology and Medical Oncology, University Hospital Würzburg, Germany;
Ulrich Keller
6 Hematology, Oncology & Tumor Immunology (CBF), Charité - Universitätsmedizin
Constantin Lapa
2 Department of Nuclear Medicine, University Hospital Würzburg, Germany;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Side effects of CXC-chemokine receptor 4 – directed Endoradiotherapy with Pentixather prior to Hematopoietic Stem Cell Transplantation
Sabine Maurer, Peter Herhaus, Romina Lippenmeyer, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, H. Carlo Maurer, Andreas K. Buck, Hans-Jürgen Wester, Hermann Einsele, Götz-Ulrich Grigoleit, Ulrich Keller, Constantin Lapa
Journal of Nuclear Medicine Mar 2019, jnumed.118.223420; DOI: 10.2967/jnumed.118.223420
Side effects of CXC-chemokine receptor 4 – directed Endoradiotherapy with Pentixather prior to Hematopoietic Stem Cell Transplantation
Sabine Maurer, Peter Herhaus, Romina Lippenmeyer, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, H. Carlo Maurer, Andreas K. Buck, Hans-Jürgen Wester, Hermann Einsele, Götz-Ulrich Grigoleit, Ulrich Keller, Constantin Lapa
Journal of Nuclear Medicine Mar 2019, jnumed.118.223420; DOI: 10.2967/jnumed.118.223420
Jump to section
Related Articles
Cited By...
- Theranostics in Hematooncology
- C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma
- Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET
- Biokinetics and Dosimetry of 177Lu-Pentixather
- CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma